Next Article in Journal
Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
Previous Article in Journal
Anti-NMDA Receptor Encephalitis and Vaccination
Article

A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors

by 1,†, 1,†, 1, 2 and 1,*
1
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of New Drug Research and Development, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2
Molecular Modeling and Drug Discovery Core for District of Columbia Center for AIDS Research (DC CFAR), Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Ge Zhang
Int. J. Mol. Sci. 2017, 18(1), 137; https://doi.org/10.3390/ijms18010137
Received: 5 December 2016 / Revised: 9 January 2017 / Accepted: 9 January 2017 / Published: 18 January 2017
(This article belongs to the Section Biochemistry)
Histone deacetylase 3 (HDAC3) has been recently identified as a potential target for the treatment of cancer and other diseases, such as chronic inflammation, neurodegenerative diseases, and diabetes. Virtual screening (VS) is currently a routine technique for hit identification, but its success depends on rational development of VS strategies. To facilitate this process, we applied our previously released benchmarking dataset, i.e., MUBD-HDAC3 to the evaluation of structure-based VS (SBVS) and ligand-based VS (LBVS) combinatorial approaches. We have identified FRED (Chemgauss4) docking against a structural model of HDAC3, i.e., SAHA-3 generated by a computationally inexpensive “flexible docking”, as the best SBVS approach and a common feature pharmacophore model, i.e., Hypo1 generated by Catalyst/HipHop as the optimal model for LBVS. We then developed a pipeline that was composed of Hypo1, FRED (Chemgauss4), and SAHA-3 sequentially, and demonstrated that it was superior to other combinations in terms of ligand enrichment. In summary, we present the first highly-validated, rationally-designed VS strategy specific to HDAC3 inhibitor discovery. The constructed pipeline is publicly accessible for the scientific community to identify novel HDAC3 inhibitors in a time-efficient and cost-effective way. View Full-Text
Keywords: HDAC3 inhibitors; anti-diabetes; virtual screening; MUBD-HDACs; benchmarking calculation HDAC3 inhibitors; anti-diabetes; virtual screening; MUBD-HDACs; benchmarking calculation
Show Figures

Graphical abstract

MDPI and ACS Style

Hu, H.; Xia, J.; Wang, D.; Wang, X.S.; Wu, S. A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors. Int. J. Mol. Sci. 2017, 18, 137. https://doi.org/10.3390/ijms18010137

AMA Style

Hu H, Xia J, Wang D, Wang XS, Wu S. A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors. International Journal of Molecular Sciences. 2017; 18(1):137. https://doi.org/10.3390/ijms18010137

Chicago/Turabian Style

Hu, Huabin, Jie Xia, Dongmei Wang, Xiang S. Wang, and Song Wu. 2017. "A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors" International Journal of Molecular Sciences 18, no. 1: 137. https://doi.org/10.3390/ijms18010137

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop